Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verrica Pharmaceuticals Inc. - Common Stock (NQ:VRCA)

7.605 +0.455 (+6.36%)
Streaming Delayed Price Updated: 11:18 AM EDT, May 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Verrica Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via Business Wire
News headline image
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
News headline image
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
From Verrica Pharmaceuticals Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.